Genovate Biotechnology Co., Ltd. (TPEX:4130)
32.00
-0.60 (-1.84%)
Feb 11, 2026, 1:30 PM CST
Genovate Biotechnology Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 163.88 | 221.6 | 180.03 | 194.17 | 198.44 | 223.21 |
Short-Term Investments | 262.6 | 259.67 | 324.03 | 282.88 | 177.98 | 197.98 |
Trading Asset Securities | 39.69 | 40.2 | 35.25 | 20 | 13 | - |
Cash & Short-Term Investments | 466.16 | 521.47 | 539.3 | 497.05 | 389.42 | 421.19 |
Cash Growth | -11.32% | -3.31% | 8.50% | 27.64% | -7.54% | -7.99% |
Accounts Receivable | 90.41 | 89.06 | 87.87 | 96.13 | 94.39 | 68.68 |
Other Receivables | 1.55 | 1.4 | 1.28 | 27.77 | 0.77 | 0.64 |
Receivables | 91.96 | 90.46 | 89.15 | 123.89 | 95.16 | 69.33 |
Inventory | 150.84 | 145.87 | 139.64 | 145.86 | 139.94 | 139.64 |
Prepaid Expenses | 7.48 | 7.34 | 3.39 | 14.79 | 10.38 | 1.47 |
Other Current Assets | 0.01 | 0.31 | 0.29 | 0.28 | 0.02 | 0.02 |
Total Current Assets | 716.45 | 765.45 | 771.77 | 781.88 | 634.93 | 631.65 |
Property, Plant & Equipment | 413.72 | 393.95 | 392.12 | 403.29 | 409.6 | 435.03 |
Long-Term Investments | 336.17 | 398.55 | 397.28 | 351.6 | 439.52 | 476.6 |
Other Intangible Assets | 3.86 | 3.11 | 4.66 | 0.8 | 1.49 | 2.51 |
Other Long-Term Assets | 28.56 | 29.16 | 34.62 | 26.87 | 29.97 | 25.04 |
Total Assets | 1,499 | 1,590 | 1,600 | 1,564 | 1,516 | 1,571 |
Accounts Payable | 32.85 | 40.28 | 32.87 | 45.91 | 35 | 36.8 |
Accrued Expenses | 26.62 | 37.49 | 29.57 | 35.55 | 29.4 | 31.21 |
Current Portion of Leases | 1.14 | 0.86 | 0.67 | 1.25 | 0.74 | 1.23 |
Current Income Taxes Payable | 2.21 | 4.39 | 1.37 | 3.27 | 3.4 | 1.94 |
Current Unearned Revenue | 2.15 | 1.96 | 4.9 | 4.73 | 4.03 | 3.92 |
Other Current Liabilities | 54.8 | 51.5 | 48.36 | 41.12 | 38.05 | 41.32 |
Total Current Liabilities | 119.77 | 136.48 | 117.73 | 131.84 | 110.61 | 116.41 |
Long-Term Leases | 0.95 | 1.73 | 0.02 | 0.59 | 0.09 | 0.83 |
Pension & Post-Retirement Benefits | - | 2.75 | 13.7 | 21.06 | 25.82 | 27.51 |
Other Long-Term Liabilities | 2.66 | 0.12 | 0.24 | 0.12 | 0.12 | 0.12 |
Total Liabilities | 123.37 | 141.08 | 131.69 | 153.6 | 136.65 | 144.87 |
Common Stock | 1,149 | 1,127 | 1,094 | 1,094 | 1,100 | 1,079 |
Additional Paid-In Capital | 210.71 | 210.66 | 210.56 | 210.51 | 208.93 | 208.75 |
Retained Earnings | 131.41 | 152.63 | 177.79 | 202.18 | 167.97 | 185.14 |
Treasury Stock | -25.72 | -25.72 | - | - | -63.03 | -63.03 |
Comprehensive Income & Other | -89.9 | -15.01 | -13.34 | -95.62 | -35.04 | 16.22 |
Shareholders' Equity | 1,375 | 1,449 | 1,469 | 1,411 | 1,379 | 1,426 |
Total Liabilities & Equity | 1,499 | 1,590 | 1,600 | 1,564 | 1,516 | 1,571 |
Total Debt | 2.09 | 2.58 | 0.68 | 1.84 | 0.83 | 2.06 |
Net Cash (Debt) | 464.07 | 518.88 | 538.62 | 495.21 | 388.59 | 419.13 |
Net Cash Growth | -11.25% | -3.66% | 8.77% | 27.44% | -7.29% | -8.25% |
Net Cash Per Share | 4.07 | 4.52 | 4.68 | 4.37 | 3.43 | 3.69 |
Filing Date Shares Outstanding | 113.75 | 113.75 | 114.91 | 114.91 | 113.33 | 113.33 |
Total Common Shares Outstanding | 113.75 | 113.75 | 114.91 | 114.91 | 113.33 | 113.33 |
Working Capital | 596.69 | 628.97 | 654.05 | 650.04 | 524.32 | 515.24 |
Book Value Per Share | 12.09 | 12.74 | 12.78 | 12.28 | 12.17 | 12.58 |
Tangible Book Value | 1,372 | 1,446 | 1,464 | 1,410 | 1,377 | 1,423 |
Tangible Book Value Per Share | 12.06 | 12.71 | 12.74 | 12.27 | 12.15 | 12.56 |
Land | 140.74 | 140.74 | 140.74 | 140.74 | 140.74 | 140.74 |
Buildings | 288.07 | 285.06 | 282.26 | 281.85 | 283.17 | 291.96 |
Machinery | 156.95 | 168.27 | 158.6 | 180.44 | 160.91 | 169.76 |
Construction In Progress | 34.82 | 2.49 | 1.88 | 0.61 | 0.41 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.